Although most assets in the pipeline for Nonalcoholic Steatohepatitis (#NASH), have thus far demonstrated modest efficacy, therapies targeting metabolism (glucose, fat, cholesterol), inflammation, and fibrosis hold promise, and engagement of multiple targets simultaneously could increase the likelihood of success.

Click here to learn more: Nonalcoholic Steatohepatitis (NASH)